Semaglutide is a GLP-1 medicine sold as Wegovy for chronic weight management and Ozempic for type 2 diabetes.
San Diego cash prices on Oct 17 2026
| Product | Monthly | Detail | Ref |
|---|---|---|---|
| Wegovy pen | $349 | Same price at every standard dose | [1] |
| Wegovy pen, first-time buyer | $199 | Two fills of 0.25 or 0.5 mg, through Dec 31 2026 | [1] |
| Wegovy tablet | $149 to $299 | 1.5 mg is cheapest; 25 mg is the top dose | [1] |
| Ozempic | $349 to $499 | Type 2 diabetes label | [5] |
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in San Diego, from $300 a month.
An advertiser pays for this labeled slot. It is not an editorial pick or an endorsement.
Budget math at a $108,077 median income
San Diego's median household income is $108,077 [3]. Twelve pen boxes at $349 come to $4,188, near 3.9% of that figure. Staying on the 1.5 mg tablet at $149 would be $1,788 a year, but the label steps most people up to doses that cost $299 [1][6].
CDC PLACES estimates 24.2% of San Diego adults have obesity and 9.2% have diagnosed diabetes [4]. With Medi-Cal out of adult weight-loss coverage since Jan 1 2026 [2], members under 21 are the main exception.
Why the 2027 list price cut matters to some San Diegans
Novo Nordisk plans to drop the Wegovy and Ozempic list price to $675 a month on Jan 1 2027 [7]. That number matters most to people on high-deductible plans, who often pay list price until the deductible is met. NovoCare's self-pay prices are set on their own.
Med spa and telehealth compounded offers
Some San Diego med spas and telehealth firms still sell compounded semaglutide. None of it is FDA-approved, and FDA counts 990 adverse event reports for compounded semaglutide, some tied to dosing mistakes that ended in hospital care [8]. California prescribers are licensed by the Medical Board of California [9]; read compounded semaglutide first.
Who should not take semaglutide
Anyone with MEN 2, or with medullary thyroid cancer in their personal or family history. Wegovy is stopped once pregnancy is found, and 2 months or more before a planned one. Stomach pain that is intense and will not ease needs prompt care [6].
The STEP 1 trial reported a 14.9% average loss at 68 weeks on 2.4 mg [10], and the extension found roughly two-thirds regained within a year off the drug [11]; see semaglutide results. Elsewhere in California and the Southwest: Los Angeles, Sacramento, Phoenix and Scottsdale. Guides: semaglutide, semaglutide near me, Ro review.
Questions people ask
What does semaglutide cost in San Diego without insurance?
NovoCare listed $349 a month for Wegovy pens and $149 to $299 for Wegovy tablets on Oct 17 2026 [1].
Does Medi-Cal still pay for Wegovy in San Diego?
Not for adult weight loss. That coverage ended Jan 1 2026, while members under 21 remain covered [2].
What share of San Diego adults have diabetes?
CDC PLACES estimates 9.2% of San Diego adults had diagnosed diabetes in 2023, and 24.2% had obesity [4].
Who licenses doctors and prescribers in San Diego?
Physicians are licensed by the Medical Board of California [9].
Is compounded semaglutide from a med spa FDA-approved?
No. FDA says compounded drugs are not FDA-approved and has received 990 adverse event reports for compounded semaglutide [8].
Will Wegovy's list price fall in 2027?
Novo Nordisk plans to cut the Wegovy and Ozempic list price to $675 a month starting Jan 1 2027 [7].
Sources
11 cited
- Wegovy self-pay offer. Novo Nordisk (NovoCare Pharmacy), Oct 17, 2026.
- California Medicaid ends coverage of GLP-1 weight loss drugs. KFF Health News, Jan 9, 2026.
- QuickFacts: San Diego city, California. U.S. Census Bureau, 2025.
- PLACES: Place Data, San Diego (2025 release, BRFSS 2023). CDC, 2023.
- Ozempic self-pay pricing. Novo Nordisk (NovoCare Pharmacy), Oct 17, 2026.
- Wegovy label (injection and tablets). DailyMed, National Library of Medicine, Jun 2026.
- Novo Nordisk announces reduction in US list price for Wegovy, Ozempic and Rybelsus. Novo Nordisk via PR Newswire, Feb 24, 2026.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
- Medical Board of California. State of California, Oct 17, 2026.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine (PubMed), Feb 10, 2021.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism (PubMed), May 19, 2022.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.